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Apolipoprotein FA genome-wide association study suggested that a R504H mutation in the proprotein convertase
PC7 is associated with increased circulating levels of HDL and reduced triglycerides in black Afri-
cans. Our present results show that PC7 and PC7-R504H exhibit similar processing of transferrin
receptor-1, proSortilin, and apolipoprotein-F. Plasma analyses revealed no change in the lipid pro-
ﬁles, insulin or glucose of wild type and PC7 KOmice. Thus, the R504Hmutation does not modify the
proteolytic activity of PC7. The mechanisms behind the implication of PC7 in the regulation of
human HDL, triglycerides and in modifying the levels of atherogenic small dense LDL remain to
be elucidated.
 2014 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Many secretory proteins are synthesized as precursors that are
subsequently cleaved at speciﬁc sites to become activated, e.g.,
receptors, hormones, growth factors, adhesion molecules, secre-
tory membrane-bound transcription factors, enzymes, and surface
proteins. Most of these cleavages are achieved by the proprotein
convertases (PCs), a family of mammalian serine proteases related
to bacterial subtilisin and yeast kexin (genes PCSK1 to PCSK9) [1].
PCs are secretory enzymes and their substrates are proteins that
are cleaved and activated or inactivated [2] along their secretory
route (lumen of the trans Golgi network – TGN, secretory vesicles,
endosomes) and/or at the cell surface. The ﬁrst 7 members of the
PC family (PC1, PC2, Furin, PC4, PC5, PACE4 and PC7) are basic
amino acid (aa)-speciﬁc proteases that cleave their substrates
predominantly after Arg residues in the general consensus motif
[R/K]-X0,2,4-R;, which shows that the cleavage sites are oftenorganized in doublets and/or contain, P4 or P6 Arg or Lys (4th or
6th residue upstream of the P1 Arg cleavage site) [3,4]. The proper-
ties of PCs, the phenotypes of their knockout (KO) mice, their
clinical importance and potential translational applications were
recently reviewed [2,5].
PC7, the most ancient and conserved basic aa-speciﬁc PC-family
member, is a type-I membrane-bound protease that is ubiquitously
expressed, but highly enriched in liver [6]. In the ER, it undergoes
an autocatalytic cleavage at RAKR141; [7,8]. The site of separation
of the inhibitory N-terminal prosegment from mature PC7 (and
hence activation of PC7) is not clear, as this is thought to occur
either in the TGN, at the cell surface or in endosomes, without
requiring a secondary cleavage. The prosegment is secreted intact
into the medium, leaving an active membrane-bound PC7 in the
cell [9]. The active enzyme is composed of a catalytic domain, fol-
lowed by a P-domain that stabilizes the catalytic pocket of the
enzyme [10], and then a transmembrane domain (TMD) and a
cytosolic tail (CT). Assays using the luminal/extracellular domain
of PC7 (soluble PC7) and ﬂuorogenic substrates indicated that this
Ca2+-dependent enzyme has an in vitro neutral pH optimum, and a
cleavage speciﬁcity for Arg; similar to Furin [3,11]. Unlike Furin,
PC7 is not secreted as a soluble/shed form, restricting its activity
to intracellular endosomes or to the cell surface [9].
In 2010, a single nucleotide polymorphism (SNP) analysis using
GWAS [12] established a strong link between high plasma levels of
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within the PCSK7 gene (frequency 11.5%), suggesting that this
SNP results in a gain-of-function (GOF) with higher levels of PC7.
Indeed, we showed that PC7 is the only convertase that can shed
within endosomes the type-II membrane-bound human TfR1 into
sol.TfR1 by cleavage at the unusual KTECER100; motif containing
basic residues at the P1 and P6 positions and a Cys at P3 [13].
TfR1 constitutes the only PC7-speciﬁc substrate known so far,
allowing the examination of the speciﬁc enzymatic properties of
the enzyme in cells. While PC7 cleaves human and rat TfR1, it
cannot shed mouse TfR1 that exhibits a P1 Lys100 instead of an
Arg100; [13]. We also showed that only membrane-bound full
length PC71-785 can shed TfR1, but not its soluble form [13], as
was the case for proBDNF [14].
Data from GWAS provided spectacular advances in identifying
genes associated with dyslipidemia and coronary heart disease
[15,16]. Very recent GWAS analyses have revealed that:
A human PC7 variant R504H (gene PCSK7 [MIM 604874]) vari-
ant rs142953140 (c.1511G>A; p.Arg504His) is associated with a
very signiﬁcant 40% increase in the levels of circulating HDL
and a30% decrease of TG (p = 3  1020) [17], likely resulting from
an increased HDL/LDL ratio [18,19]. This is the ﬁrst evidence that
reveals physiological functions of PC7 in relation to cardiovascular
homeostasis and vascular calciﬁcation. It is noteworthy that the
heterozygote R504H mutation was detected in a cohort of 14,330
black African Americans, occurring at a frequency of 0.2%
(1:500 individuals), but not at all in a cohort of 42,208 white Cau-
casians [17]. This variant could thus be an ancient mutation that
was not exported frequently out of Africa during the ﬁrst migration
of humans out of this continent, as was reported for some PCSK9
variants [20].
Accordingly, the authors showed that over-expression of
human PCSK7 in the liver of mice using a recombinant Adeno-asso-
ciated virus (AAV8) resulted in a 15% reduction of HDLc in the
ﬁrst week and 45% increased TG in the second week. This sug-
gested that the rs142953140 variant may result in a decreased
PC7 level and/or activity, which may rationalize the associated
enhanced HDLc and decreased TG levels in black African Americans
[17]. It is interesting to note that Arg504 is in the critical P-domain
of PC7, the latter thought to be important for the folding of the pro-
tein, and is replaced by His in the rat and mouse and by Asn in
Xenopus laevis homologues (Fig 1A). Therefore, it was surprising
that this variant was associated with high HDL and low TG levels,
though it is coincident with the lower ratio of HDL/LDL found in
humans versus rodents. Rodents exhibit a high HDL/LDL ratio with
low LDL in the circulation, thought to be due to the absence of cho-
lesterol ester transfer protein in mouse, which exchanges choles-
terol esters and TG from HDL to VLDL/LDL. However, PC7 exerts
species-speciﬁc functions, evidenced by its inability to shed mouse
TfR1 [13].
2. Materials and methods
2.1. Cellular transfections
HuH7 and HEK293 cell lines were grown in Dulbecco’s modiﬁed
Eagle’s medium (DMEM, Invitrogen) with 10% foetal bovine serum
(FBS, Invitrogen). All cells were maintained at 37 C under 5% CO2.
Using Lipofectamine (Invitrogen) HuH7 cells were co-transfected
with 800 ng of hTfR1-V5 (V5-tagged) and either 800 ng or 8 ng of
empty vector control, human PC7 wild type (WT) or its R504H
mutant or 800 ng of rat PC7. HEK293 cells were co-transfected
with myc-tagged human Sortilin [14] and either WT PC7 or its
R504H mutant with Effectene (Qiagen) according to the manufac-
turer’s instructions. At 24 h post-transfection, cells were washed,followed by incubation for an additional 20 h in serum-free med-
ium. Cells and conditioned media were then collected for Western
blot analysis. The separated proteins were revealed using mAb V5-
HRP, PC7 or b-actin antibodies and a rabbit HRP-conjugated sec-
ondary antibody [13].
2.2. Isolation, culture, and transfection of mouse primary hepatocytes
Mouse primary hepatocytes were isolated from 8- to 10-week-
old male livers using a two-step collagenase perfusion method
[13]. In 3.5-cm Petri dishes coated with ﬁbronectin (0.5 mg/ml,
Sigma), 5  105 cells were seeded in Williams’ medium E (Invitro-
gen) with 10% FBS. After 2 h, the medium was replaced with
hepatozyme medium (Invitrogen) for 12 h prior to transfection.
We ﬁrst generated cDNAs of human and mouse Apolipoprotein F
(ApoF) tagged with V5 at their C-termini. These were co-transfec-
ted in mouse primary hepatocytes with cDNAs coding for either an
empty vector control, WT PC7 or its R504H mutant. Transfections
were performed with Effectene using a total of 4 lg of cDNA, fol-
lowing the manufacturer’s instructions. Cell lysates and media
were collected 48 h post-transfection and subjected to SDS–PAGE
separation (14% Tris-Tricine) followed by Western blot analysis.
2.3. In situ hybridization histochemistry of ApoF and PC7 mRNAs in
mouse liver
Cryosections (10 lm thick) were prepared from livers of 3-
month-old WT mice, ﬁxed in 4% formaldehyde, and hybridized as
previously described [14] with mouse sense (negative control)
and antisense cRNA probes. The latter probes corresponded to cod-
ing regions of mouse PC7 (residues 1–213) or ApoF (full length),
and were synthesized using 35S-UTP (PerkinElmer).
3. Results and discussion
In this work we took advantage of our complete Pcsk7 knockout
(KO) mouse model [14] to evaluate the plasma lipid proﬁles in the
presence and absence of PC7. Surprisingly, our results indicated no
signiﬁcant changes of TG, total cholesterol and HDLc in 3-month
old Pcsk7 KO mice compared to WT mice for either males or
females (Table 1), also conﬁrmed by FPLC analyses (not shown).
Furthermore, plasma analyses by ELISA revealed no difference in
the levels of circulating PCSK9 [21] in WT and Pcsk7 KO mice
(not shown). This result suggests that under a normal Chow diet,
and contrary to human PCSK7 overexpression, the lack of expres-
sion of mouse Pcsk7 is not signiﬁcantly involved in regulating HDLc
TG, or PCSK9. However, it was still plausible that the PCSK7
rs142953140 variant could result in lower levels of PC7 expression,
or represent a loss-of-function (LOF) mutation resulting in a
reduced PC7 enzymatic activity.
Since overexpression of PC7 does not cause ER stress to cells [9],
we sought to determine whether an Arg504 to His mutation
(R504H) may inﬂuence the cellular proteolytic activity of PC7.
Accordingly, we evaluated ex vivo the cleavage of two reported
human PC7-substrates: transferrin receptor 1 (hTfR1) [13] and
proSortilin [14]. We also analyzed the processing of apolipoprotein
F (apoF) and angiopoietin-like 4 (ANGPTL4) implicated in HDL and/
or triglyceride metabolism [22,23]. (a) In human hepatoma HuH7
cells, the R504H mutant is just as active as WT PC7 in shedding
hTfR1 into its secreted soluble form (s-hTfR1; Fig. 1B). However,
when the cells expressed 100-fold less cDNA levels of PC7 WT or
its mutant compared to its substrate hTfR1 we noticed a trend
towards lower (15%) activity of the R504H mutant (Fig. 1C).
Finally, we also observed that rat PC7 (Fig. 1A) sheds equally well
the hTfR1 versus human PC7 (Fig. 1D). (b) Similarly, in human
Fig. 1. Processing of PC7 substrates. Cleavage of human transferrin receptor 1 (hTfR1), human proSortilin and mouse proApolipoprotein F (proApoF) by wild type (WT)
human PC7 and its R504H mutant or by rat PC7. (A) Comparison of human, mouse, rat and xenopus (Xen.) PC7 sequences. (B–D) Western blot analysis of the lysates and 20 h
conditioned media of HuH7 cells co-transfected with 800 ng of hTfR1-V5 and either 800 ng (B, D) or 8 ng (C) of empty vector, human PC7 WT or its R504H mutant or rat PC7.
The separated proteins were revealed using mAb V5-HRP, PC7 or b-actin antibodies and a rabbit HRP-conjugated secondary antibody. (E) Western blot analysis of cell lysates
from HEK293 cells transiently transfected with human proSortilin-c-Myc and either empty vector, human PC7 WT or its R504H mutant. Proteins were revealed using mouse
c-Myc, rabbit PC7 or rabbit b-actin antibodies and the corresponding HRP-conjugated secondary antibody. (F) Western blot analysis of lysates and 48 h conditioned media
from mouse primary hepatocytes co-transfected with human or mouse proApoF-V5 and either empty vector, human PC7 WT or its R504H mutant. The separated proteins
were revealed using mAb V5-HRP, PC7 or b-actin antibodies and a rabbit HRP-conjugated secondary antibody.
Table 1
Plasma triglycerides, total and HDL cholesterol, glucose and insulin in Pcsk7+/+ and
Pcsk7-/- mice.
Male Female
Pcsk7+/+ Pcsk7-/- Pcsk7+/+ Pcsk7-/-
Triglycerides (mg/dL) 43.2 ± 3.3 45.1 ± 3.6 27.8 ± 3.6 25.1 ± 2.9
Total cholesterol (mg/dL) 112.7 ± 5.1 113.6 ± 5.9 94.4 ± 5.2 95.4 ± 1.6
HDL cholesterol (mg/dL) 99.6 ± 3.9 104.7 ± 5.2 84.6 ± 5.0 89.1 ± 1.7
Glucose (mmol/L) 8.3 ± 0.5 8.1 ± 0.6 7.7 ± 0.4 8.8 ± 0.6
Insulin (ng/mL) 1.5 ± 0.3 1.3 ± 0.2 0.9 ± 0.2 0.8 ± 0.1
Values are means ± S.E.M. Plasma samples were collected after 4 h fasting from
3- to 4-month-old C57BL/6J Pcsk7+/+ or Pcsk7-/- mice. Triglycerides were determined
using the Wako kit (n = 18–19 mice/group for male and n = 8 mice/group for
female). Total and HDL cholesterol measurements were performed on a Roche
Cobas Integra 400 plus analyzer (n = 6 mice/group for male and n = 5 mice/group for
female). Glucose levels were determined using an automatic glucometer and insulin
levels were measured using the Mouse Insulin Ultrasensitive ELISA Kit from Alpco
Diagnostics (n = 12–14 mice/group for male and n = 6 mice/group for female).
Abbreviation: HDL, High density lipoprotein.
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tilin with WT PC7 or its R504H mutant revealed that both forms
can completely process proSortilin into Sortilin (Fig. 1E).Altogether, these results indicated that the presence of the His504
did not appreciably affect the ability of PC7 to be autocatalytically
activated (ratio of PC7 to proPC7 is unchanged) or process hTfR1
and proSortilin.
While Sortilin has been genetically linked to LDL, likely due to
its enhanced degradation of apolipoprotein B in lysosomes [24],
it has not been correlated to HDL or TG. Therefore, we sought to
examine the possibility that PC7 or its mutant can differentially
process ApoF, a potential substrate that is found at the periphery
of HDL particles [22]. In situ hybridization histochemistry analysis
[14] revealed that the mRNAs of PC7 and ApoF co-localize in liver
(Fig. 2), supporting the possibility that apoF may be a substrate of
PC7. Indeed, our data showed that overexpression of PC7 in mouse
primary hepatocytes can process mouse and less so human pro-
ApoF into ApoF (Fig. 1F) likely at RAKR165; and RVGR164;, respec-
tively, as previously hinted [22]. However, like for hTfR1 and
proSortilin, WT PC7 or its R504H mutant process equally mouse
and human proApoF (Fig. 1F). Such results revealed that proApoF
constitutes a novel PC7 substrate, and indicated that the presence
of the His504 did not affect the ability of PC7 to cleave it. Further-
more, as previously reported for angiopoietin-like 3 (ANGPTL3)
[25], Furin and PC5/6A are the best convertases for ANGPTL4, and
Fig. 2. Comparative localization of apoF and PC7 mRNA in mouse liver. In situ hybridization localization of ApoF and PC7 mRNA in the mouse liver at anatomical level. (a)X-
ray ﬁlm autoradiography showing apoF mRNA antisense labeling ubiquitously distributed throughout the liver (Li); dark ﬁeld illumination; 5-day exposure time. (b) Adjacent
section with PC7 mRNA labeling in the liver (Li); 5-day exposure time. (c) Control (Ctr) PC7 sense mRNA labeling; 5-day exposure time. (d) Emulsion autoradiography
showing apoF mRNA labeling seen as dark silver grains under light ﬁeld illumination. Labeling is mostly concentrated in hepatocytes (He); 2-day exposure time. (e) PC7
mRNA labeling (arrow) within liver hepatocytes (He); 10-day exposure time. Magniﬁcations: (a–c) 6.4 and (d and e) 225.
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shown).
It was suggested that atherogenic small dense LDL particles
(sdLDL) contribute to increased cardiovascular disease and meta-
bolic syndrome even when LDLc levels are within the normal range
[26]. Very recently, it was reported that the levels of sdLDL were
correlated with the PCSK7 SNP rs508487 [27] located in the 3’
non-coding sequence of PC7 mRNA. The authors report that each
copy of the minor allele at this SNP raise sdLDL by 4 mg/dl and
triglycerides by20 mg/dl, and is signiﬁcantly associated with cor-
onary heart disease. Furthermore, rare variants of PCSK7 were also
associated with increased circulating levels of sdLDLc by 7.5 mg/
dl. We have tested these variants as well as the D186G, R316C and
the frame-shifted sequence at L506P. Our data showed that the
latter result in complete loss of function (LOF) of PC7 activity on
the processing of hTfR1 (not shown). In that context, the authors
suggest that LOF of PCSK7 is associated with increased risk of car-
diovascular disease.
However, our data on Pcsk7 KO mice did not reveal any signiﬁ-
cant changes in either LDL, HDL, or triglycerides levels, under a
Chow diet (Table 1). From plasma FPLC analyses [25] the lack of
changes in lipids in the absence of PC7 was also conﬁrmed (not
shown). However, at the present time we cannot exclude that
under a high fat or cholesterol diet the absence of PC7 may inﬂu-
ence the lipid proﬁles. Furthermore, we also did not detect any
changes between genotypes in either circulating insulin or glucose
levels (Table 1).
In conclusion, our data associated with the study of Peloso et al.
[17] suggested that the presence of the Arg504 does not modify the
proteolytic activity of PC7, even though it is implicated in the reg-
ulation by PC7 of human cardiovascular homeostasis by an as yet
undeﬁned mechanism. Since no change in enzymatic activity of
PC7 was detected on four substrates for the R504Hmutant, we pre-
sume that the implication of PC7 R504H in lipid homeostasis mayeither be due to a difference between human and mouse lipid
metabolism, or that it does not require the enzymatic activity of
PC7. It will however be important in the future to ﬁgure out
whether the R504H mutation is really involved with altering HDL
levels, or if this mutation is associated with another mutation that
is the direct cause for observed changes in HDL.
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